Centers for Disease Control and Prevention
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Centers for Disease Control and Prevention sits in the top decile of US sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count).
Centers for Disease Control and Prevention: 139 sponsored US clinical trials, 3 recruiting.
Centers for Disease Control and Prevention sponsors 139 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 131 completed. 18 of these trials are in Phase 3-4 (later-stage) and 62 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 12 trials.
Top-decile sponsor footprint
Centers for Disease Control and Prevention ranks in the top decile of sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
131 of 134 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
139 total, page 3 of 3
CD-ROM Intervention for Prostate Cancer Screening
NCT00164437
Multi-site Study of Rapid Diagnostic Syphilis Assays
NCT00300534
Project CHOICES Efficacy Study
NCT00153478
Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change
NCT00119067
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
NCT00153543
Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users
NCT00164372
Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients
NCT00137670
Neurocognitive Habilitation for Children With Fetal Alcohol Syndrome (FAS)/Alcohol-Related Neurodevelopmental Disorder (ARND)
NCT00164346
Study to Improve Partner Services for STD Prevention
NCT00207467
Fetal Alcohol Syndrome: Socio-Cognitive Habilitation
NCT00164229
Intervening With Children/Adolescents With FAS/ARND
NCT00164528
Fetal Alcohol Syndrome/ARND Research Consortion
NCT00164554
Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships
NCT00164307
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
NCT00153556
Behavioral Intervention Trial for HIV-infected Injection Drug Users
NCT00146445
Testing the Effectiveness of VOICES as Implemented by STD & HIV Prevention Agencies in the US and PR
NCT00164619
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
NCT00023452
An STD Prevention Intervention for Men Newly Released From Jail
NCT00260780
Optimizing Strategies to Improve STD Partner Services
NCT00207454
Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents
NCT00141999
Partner Notification Intervention for STD Clinics.
NCT00207571
Treatment and Management of Women With Bleeding Disorders
NCT00111215
The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services.
NCT00207493
TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
NCT00023374
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
NCT00023439
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
NCT00023387
TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB
NCT00023400
TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
NCT00023413
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
NCT00153517
Legacy for Children, an Early Intervention Study to Promote Optimal Child Development in Low-income Families
NCT00164697
Parents Matter!: Interventions to Promote Effective Parent-Child Communication
NCT00137943
TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB
NCT00023348
TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
NCT00023426
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
NCT00023361
Community Intervention Trial for Youth (CITY) Study
NCT00164580
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
NCT00139113
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
NCT00023335
ED Intervention to Reduce Risky Behaviors in Drivers
NCT00164294
Intimate Partner Violence (IPV)Screening in Health Care Clinics in Rural South Carolina
NCT00164567
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 36 |
| Phase 3 | 9 |
| Phase 4 | 9 |
Therapeutic Areas
What is open in the Centers for Disease Control and Prevention pipeline
3 recruiting of 139 indexed (2% open); 131 completed (94%).
Phase mix: 18 late (III/IV) vs 62 early (I/II) (early-phase heavy).
Top condition: HIV Infections (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Centers for Disease Control and Prevention: open-pipeline peers nationwide
Peers matched on 139 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Centers for Disease Control and Prevention sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 139 trials (± recruiting share)
- Barbara Ann Karmanos Cancer Institute · 139 trials · 12% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 138 trials · 3% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Baxter Healthcare Corporation · 2% recruiting · 46 trials
- USDA, Western Human Nutrition Research Center · 2% recruiting · 47 trials
- Sun Pharmaceutical Industries · 2% recruiting · 48 trials
- NSABP Foundation · 2% recruiting · 44 trials
Related
What to do with this Centers for Disease Control and Prevention page
139 registered trials is a research-attention snapshot, not an endorsement of Centers for Disease Control and Prevention or any single study.
- 3 of Centers for Disease Control and Prevention's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition Centers for Disease Control and Prevention studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Centers for Disease Control and Prevention pipeline card: 139 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.